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Abstract

Malaria is a devastating disease that continues to affect millions of people
worldwide every year. Specifically, Plasmodium falciparum is the most common human
malaria parasite, particularly in sub-Saharan Africa. P. falciparum causes the most
malignant and debilitating symptoms with the highest mortality and complication rates.
Even with the worldwide efforts of many researchers and organizations, the road to
discovering a vaccine has been difficult and challenging. Due do to the improvements in in
vitro liver stage assays as well as rodent models of mammalian malaria, pre-erythrocytic
stages of malaria have become a more accessible target for experimental studies. These
vaccine candidates target Plasmodium sporozoites in the liver and liver stages to prevent
development to the blood-stage forms, which is responsible for the debilitating symptoms
of the disease. Scanning electron microscopy has been used for decades to provide insight
on the morphology and topography of specimens, which cannot be seen through a light
microscope. The purpose of this study was to analyze the morphology of sporozoites with
some target antibodies. Sporozoites have previously shown uncharacterized appearances
and development in an immunofluorescent stain at different concentrations of particular
antibodies. With this further understanding on the morphological impact few of the target
antibodies have on sporozoites through scanning electron microscopy, further grasp can be
acquired.
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Chapter One
Introduction

Malaria is a life-threatening disease affecting millions of people world- wide. In
2015 alone, there were an estimated 214 million cases of malaria with over 438,000 deaths
(WHO, 2016). Those who reside in the poorest countries are especially vulnerable,
primarily children under the age of 5. Not only does this debilitating disease have an impact
on the population health, the economic consequences can also be devastating. In African
countries alone, malaria drains as much as 2% of the Gross Domestic Product (Mota &
Rodriguez, 2002). In the past 15 years the malaria mortality rate has dropped over 45%
predominantly due to widespread funding for malaria control interventions such as longterm insecticidal nets, access to artemisinin combination therapy (ACT) and indoor
residual spraying programs (CDC, 2016). While there has been an overall global reduction
in disease burden, the continued spread of drug and insecticide resistance makes
eliminating malaria both crucial and worthwhile (Stresman, Cameron, & Drakeley, 2017).
Malaria is caused by protozoan parasites belonging to the genus Plasmodium (WHO,
2016). There are five species that cause infection in humans, Plasmodium falciparum,
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and Plasmodium knowlesi. P.
falciparum (P.f.) is responsible for the majority of malaria deaths globally and is the most
prevalent species in Sub-Saharan Africa (CDC, 2016). Aside from P. falciparum, P. vivax is
1

the most widely distributed parasite outside of Africa and is primarily located in Southeast
Asia and Latin America (CDC, 2016).

Life Cycle
The malaria parasite is known to have a complex life cycle. The disease is transmitted once
a malaria-infected Anopheles mosquito blood feeds on a human whereupon ~100
sporozoites are injected into the mammalian circulation and travel through the blood
stream via gliding motility (Stewart & Vanderberg, 1988). Sporozoites have evolved to be
well-adapted to its host as infection can occur with as little as 10 sporozoites (Ungureanu
et al., 1976). The sporozoites travel through the bloodstream to quickly reach the liver of
the mammalian host, and recognize the liver via a process thought to be mediated by
circumsporozoite (CS) protein (Mota & Rodriguez, 2002). Once the sporozoites arrive in
the liver, they infect hepatocytes, and within 7-14 days they develop into schizonts. When
the schizonts are fully matured, the hepatocyte ruptures, releasing thousands of
meorozoites into the blood stage. After this stage, the parasites reproduce asexually in the
erythrocytes and infect red blood cells. The ring stage trophozoites mature into schizonts,
which rupture and release meorozoites. At random, some parasites also differentiate into
gametocytes. Blood stage parasites are responsible for the clinical manifestation of the
disease (CDC, 2016).

Symptoms
The symptoms seen in patients can be categorized as uncomplicated or severe.
Symptoms of P. falciparaum occur every second day and the uncomplicated symptoms can
2

sometimes include a cold stage, a hot stage, and finally a sweating stage. More commonly,
patients can present with a combination of fever, chills, sweats, headaches, body aches,
nausea and vomiting, and general malaise (CDC, 2016). The severe form of malaria
presents with manifestation of severe anemia, cerebral malaria (impairment of
consciousness, seizures, coma or other neurologic abnormalities), hemoglobinuria, acute
respiratory distress syndrome, acute kidney failure and more. Manifestation of severe
malaria is considered a medical emergency and is strongly advised to treat aggressively
and urgently (CDC, 2016).

Treatment
Factors which determine how a malaria patient is treated depends on the species of
the infecting parasite, the clinical status of the patient, pregnancy, drug allergies, the area
where the infection was acquired, and any other accompanying illnesses or conditions all
can effect how a patient is treated (CDC, 2016). P. falciparum can cause rapidly progressive
illness or death compared to other plasmodium species. For treatment of uncomplicated P.
falciparum, WHO recommends arteminisin-based combination therapy, known to have
potent activity against all blood stages of P. falciparum parasites. ACTs are known as the
most effective antimalarial medicines available today for uncomplicated malaria and are
made by combining two active ingredients with different mechanisms of action. There are 5
ACTs used against P. falciparum (WHO, 2016). However, the continued use of oral ACT is
considered to be a major factor contributing to resistance to arteminisin derivatives.
Artemisinin resistance (ART) is defined as a high prevalence of the delayed parasite
clearance phenotype and a K13 resistance-associated mutation in an individual patient
3

(Fairhurst & Dondorp, 2016). There is still little known about artemisinin-resistant P.
falciparum, however, the increasing incidence of ACT failures have posed a real threat to
malaria treatment and elimination efforts worldwide (Dondorp et al., 2011).

Malaria Vaccine
Efforts to develop a long lasting and effective vaccine against malaria have been the
focus of many researchers globally. Beginning in the 1930s, the focus was centralized on
inactivated or killed parasites, which failed to generate a protective immune response
(Ouattara & Laurens, 2015). Beginning with ducklings then moving to rodents, subsequent
vaccine development efforts led to the first human malaria vaccine trial (Clyde et. al, 1973).
Vaccine clinical trials of the modern era began in the 1990s, which utilized sequences from
3 P. falciparum blood-stage antigens and the circumsporozoite protein (CSP). Studies from
these trials showed protection in South America but none in Africa (Graves & Gelvband,
2006). After 35 years, advances such as parasite cultivation methods and sequencing of the
parasite genome have given hope to the discovery of a vaccine, yet there are still unsolved
obstacles.
While there are several categories of vaccines being developed for protection in the
pre-erythrocytic, blood stage and sexual stages of the parasite, there is still a long way to go
(Chia, Goh, & Renia, 2014). The rationale behind developing a vaccine to protect against
malaria comes from previous studies where naturally acquired immunity to malaria was
shown to protect against malaria in an age-dependent and exposure dependent manner
(Chia et al., 2014). Vaccine development is limited by the lack of understanding of
mechanisms in a natural transmission setting. Vaccine efforts have aimed at the stages of
4

sporozoite invasion and liver stage development; however, long-term immunity has not yet
been achieved (Hill, 2011) . To date, the RTS, S malaria vaccine is the candidate furthest
advanced through clinical trials and has provided some protection against P. falciparum
infection in humans (Kazmin et al., 2017) and its efficacy showed only partial protection
with age specificity. More importantly, vaccine efficacy was undetectable 3 years after
vaccination (Bejon et al., 2013). Research has contributed the moderate efficacy to the lack
of fully understanding the mechanism of action of protective immunity (Kazmin et al.,
2017).
The pre-erythrocytic (PE)- stage of the Plasmodium parasite is an attractive target
for vaccine development. This stage is metabolically active but symptomatically silent as a
preparatory phase in the parasite’s life cycle (Duffy et al., 2012). This stage is key for many
reasons; the number of infected hepatocytes is low (Medica & Sinnis, 2005), human
parasites take 7 days or longer to complete development (Mauduit et. al, 2009), and the
infected hepatocyte is able to present parasite antigens to immune effector cells (Hoffman
et. al, 1987). Functional immunoassays using an in-vitro malaria liver-stage infection model
have been used to study the development of parasites in the liver for decades (House,
Hollingdale et. al, 2009). These models have helped in discovery and characterization of
sporozoite and liver-stage antigens, help validate potential malaria vaccine candidates and
to search for immunological correlates of protection in humans. These assays have varied
over time and between laboratories, but the underlying ideas remain similar. First, test
serum is pre-incubated with sporozoites from Anopheles female mosquito. Following, the
serum/sporozoite mixture is added to a layer of human hepatocytes or a similar substance.
Next, incubation is done to allow sporozoites to invade the hepatocytes. Finally, cells are
5

fixed and stained to allow for processing and imaging (Silvie, 2004). Even though these
assays were developed to support validation and evaluation of vaccine candidates, a
challenge has been the reliability from these assays to correlate with in-vivo protection
(Nussenzweig, Vanderberg, Most, & Orton, 1967). Their effects currently only measure the
effects of humoral immunity (House, Hollingdale et. al, 2009). As discussed previously, a
major difficulty has been in finding a vaccine immunogen that elicits a protective immune
response in humans (Potocnjak, Yoshida, Nussenzweig, & Nussenzweig, 1980).
Through the use of irradiated sporozoites the Plasmodium circumsporozoite protein
was identified many years ago to be a crucial antimalarial vaccine targets (Gonzalez-Ceron
et al. 1998). CSP of all Plasmodium species have a central region, variable in length, with
species-specific repeated amino acid sequence and their location of the surface of infective
sporozoites attributes to their immunogenicity. The reaction, which consists of the
formation of a thread-like precipitate at the posterior end of the sporozoites showed host
protection at high concentrations (Potocnjak et al., 1980). The polymorphic cs gene has
diversity within its regions, which encode epitopes recognized by the human immune
system (Egan et al., 1993). Previous studies also confirm there is a relationship between
sporozoite motility and invasion and CSP antibodies function by blocking sporozoite entry
and development into hepatocytes through a concentration-dependent inhibition(Stewart,
Nawrot, Schulman, & Vanderberg, 1986). Recent experiments in the Adams Lab revealed
immunofluorescent stained P. falciparum parasites after exposure to various
concentrations of anti-PfCSP (2A10), and anti-PvCSP (B483V), and no antibody control.
Visualization with the culture revealed an uncharacterized appearance and development as
shown in Figure 1 (Roth, 2014). Although the “CSP reaction” is a classic phenomenon,
6

which sporozoite surface shedding occurs when the parasites are exposed immune antiCSP antibody (Nussenzweig et al., 1967), this is not well characterized for other antigens
and the post infection affect has not been previously reported. The purpose of this study
was to utilize Scanning Electron Microscopy to further visualize the morphology of
sporozoite and analyze the uncharacterized appearance.

Figure 1. ILSDA P. falciparum liver stage development (Roth, 2014). Representative images
of immunofluorescent stained P. falciparum parasites after exposure to various
concentrations of anti-PfCSP (2A10), anti-PvCSP (B483V), and no antibody control. PfSGS
exposure to higher concentrations (2.5 and 25 µg/mL) of 2A10 show a decreased ability of
sporozoites to invade and develop LS forms. Visualization of the culture system show
sporozoite interaction with 2A10 reveal an uncharacterized appearance and development.
Images at high resolution imaging with scale bars at 5 µm.
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Introduction to Scanning Electron Microscopy
A scanning electron microscope (SEM) is a powerful imaging tool, which utilizes a
focused beam of electrons, to image 3-dimensional topography of biological specimens at
high magnification (Fischer, Hansen, Nair, Hoyt, & Dorward, 2012). One is able to describe
the morphology of structures using high resolution with this type of microscope to develop
valid conclusions about the characterization of solid materials (Beane, 2004). The
microscope was first developed by professor Dr. Charles Oatlev in the 1950s, and since has
been used as a valuable resource for data analysis. A SEM requires a stable power supply,
vacuum and cooling system and a vibration-free space. To visualize images with SEM, the
process begins with an electron gun, which generates an electron beam down a column
onto multiple electromagnetic lenses. These lenses are magnetic coils adjusted to focus a
stream of electrons that are then scanned repetitively across the surface of a specimen
inside the microscope, releasing a signal of scattered electrons from the sample surface.
Difference in surface topology leads to variations in the released signal, which is captured
and converted, into an observable image (Argast & Anne, 2004). With an SEM operator,
magnification can also be controlled for optimal surface visualization.
Before samples can be analyzed by SEM they must be adequately prepared by
chemical fixation and dehydration. The most common way to chemically fix samples is
short-term incubation in glutuaraldehyde (or glutaraldehyde-formaldehyde mixture)
followed by alcohol dehydration (Fischer et al., 2012). To completely remove all remaining
water a final treatment is needed. While critical point drying (CPD) has been the most
common and universal method for full dehydration, Hexamethyldisilazane (HMDS) has
been used in replace of CPD due to its quickness, ease of use and price (Braet, De Zanger, &
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Wisse, 1997). Depending on the specimen in question, the results between HMDS and CPD
can be equivalent (Nation, 1983). After dehydration non-conductive samples like biological
samples must be treated to make their surface conductive for the electron beam. Sputter
coating is used after fixing and drying specimens and helps to minimize damage and
improve topographical contrast. This improves imaging using secondary electron detection
and the choice of metal should be considered cautiously depending on the sample (Fischer
et al., 2012). Resolution can reach up to 10 nanometers and the intense interactions, which
occur at the exterior surface of specimens, provide great depth into the understanding of
samples. SEM can be an essential tool in the research field as well as in technological and
industrial applications.
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Chapter Two
Materials and Methods

Plasmodium falciparum sporozoites
Anopheles Stephensi mosquitos with Pf line Navy, NF54 were shipped through World
Courier from the Malaria Institute at the John Hopkins University Bloomberg School of
Public Health. Mosquitos were cleaned and sporozoites were dissected from the salivary
glands of the An. stephensi mosquitoes 15-20 days after infection and directly placed into
RPMI 1640 medium. An aliquot of sporozoites were counted with a hemocytometer to
obtain the desired amount of sporozoites (10,000 per well).
Thirteen mm round Thermanox® coverslips were coated with Poly-L-Lysine 0.1%
solution to improve adherence of sporozoites to coverslips. The chosen antibodies were
diluted in RPMI 1640 medium to obtain the desired concentrations (Table 1).
Approximately 10,000 sporozoites per antibody and concentration were obtained from the
fresh mosquito dissection and incubated for 20 minutes in a selected well from the
polystyrene 24-well plate. After incubation, unbound sporozoites and media were
removed. The remaining sporozoites were fixed with 300 µL Glutaraldehyde 2.5% in 0.1M
Sodium Cacodylate Buffer (SCB), pH 7.4 for 15 minutes. The solution was then removed
and 0.1 M SCB was added for storage in 4°C.
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Table 1. The chosen antibodies and concentrations used for the experiment
Antibody
Concentrations (µg/mL)
CSP 2A10
25
2.5
CSP 210
25
2.5
AMA1
25
2.5
CELTOS 4D1
25
2.5
CELTOS 4H12
25
2.5

0.25
0.25
0.25
0.25
0.25

Chemical preparation for the preservation of sporozoites
Sodium cacodylate buffer was removed and 0.25 mL of Osmium Tetroxide aqueous
solution was added drop wise. After 30 minutes, solution was removed and the coverslips
were washed 3 times for 5 minutes each with the buffer. Following, dehydration was
performed with a graded ethanol series by subsequent exchanges (Table 2). Once all
ethanol was removed, a formulation of 50% Hexamethyldisilazane and 50% EtOH was
added for twice for 15 minutes followed by 0.5 mL pure Hexamethyldisilazane twice for 15
minutes.
Table 2. Graded ethanol series for dehydration step in chemical preparation of specimens
% EtOH
Repetitions
Time (minutes)
35
2
1
70
2
1
95
2
1
100
3
5
Coverslips were attached onto aluminum mounts made from ultra-pure aluminum,
which had a double-sided carbon adhesive tab applied. Colloidal graphite, carbon particles
suspending in isopropanol, was used to improve adherence and ensure the entire coverslip
had contact with carbon to improve imaging. A sputter coater was used with a pump hold
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time of 5 minutes, H:M:S of 40 seconds and Au:Pd of 60:40 for the choice of metal.
Specimens were then mounted onto an aluminum stub holder suitable for use in SEM.

Imaging and data analysis
A high-performance JEOL JSM6490 Scanning Electron Microscope was used on high
vacuum mode to view the surface and 3D organization of the sporozoites. An EDAX Genesis
energy-dispersive x-ray analysis system was used for elemental analysis. Once sporozoites
were placed in the machine, the stage was elevated to 16 mm and the resolution was
lowered to 6 kV for optimal imaging. All sporozoites were measured with the scalar setting
through the software and images were taken with magnification between 7,500x – 15,000x.
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Chapter Three
Results

Four antibodies along with a positive control antibody were tested for the duration of the
experiment: anti-CSP2A10, anti-PvCSP210, AMA1, CelTOS 4D1, CelTOS 4H12, CelTOS 2F12
each at 25 µg/mL, 2.5 µg/mL and 0.25 µg/mL. Table 3 shows the antigen along with their
description and vaccine mechanism.
Table 3. Description of the current malaria vaccines used in this study along with the
mechanisms involved
Antigen
Description
Vaccine Mechanism
CSP
Circumsporozoite protein
Inhibit sporozoite motility; prevent
hepatocyte invasion
AMA1
Apical membrane antigen 1
Target merozoite ligand that
mediates erythrocyte and
sporozoite invasion (1-5)
CelTOS
Cell-traversal protein for ookinetes
Inhibit sporozoite motility; prevent
and sporozoites
hepatocyte invasion (6-7)
1-5. (Anders et al., 1998; Deans et al., 1982; Silvie et al., 2004; Thomas, Deans, Mitchell,
Alderson, & Cohen, 1984; Waters et al., 1990). 6-7. (Bergmann-Leitner, Legler,
Savranskaya, Ockenhouse, & Angov, 2011; Bergmann-Leitner et al., 2010)
Two sets of 50 sporozoites for each concentration of each antibody were imaged to
accumulate a total of 100 sporozoites analyzed. The sporozoites were classified as normal
(smooth, elongated) or with different abnormal appearances, which were broken down
according to the descriptions in Table 4.
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Table 4. Definitions of the abnormal appearances seen through Scanning Electron
Microscopy
Type
Description
Rugged
Wrinkled, jagged sporozoite surface
Damaged
Physical harm affecting sporozoite shape
Loose surface membrane Sporozoite surface membrane is thinner and weaker, causing
disattachment
Surface Membrane Tear
Tear in the surface membrane
Sporozoites incubated with anti-PvCSP210, reactive the 210 variant of P. vivax CSP,
was used as the negative antibody control in addition to a no antibody control. There were
a total of 91 sporozoites with a normal appearance of smooth and elongated in the negative
control sample. 9 sporozoites had some minor damage or a surface membrane tear. This
was compared to the positive control anti-PvCSP210, along with the other antibodies
chosen for this study.
Anti-PvCSP210 and the sporozoites with no antibody were compared as seen by
Figure 1 and Figure 2. Figure 1 shows the number of anti-PvCSP210 with a normal
appearance at 25 µg/mL, 2.5 µg/mL and 0.25 µg/mL were 80, 82, and 87 sporozoites
respectively. Figure 2 compares the subsections of abnormal differences between antiPfCSP MAB2A10 and no antibody. For the differences within the uncharacterized
sporozoites, all types appeared within every concentration of antibody.
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Number of Sporozoites

Comparison Between Pf with no
Antibody and CSP 210
100
80
60

Spz with no ab

40

CSP 210 25

20

CSP 210 2.5
CSP 0.25

0
Smooth, Elongated

Abnormal

Morphological Differences

Figure 2. 100 P. Falciparum sporozoites with no antibody (as the negative control) were
compared with 100 anti- CSP 210 induced sporozoites (as the positive control) at 25
µg/mL, 2.5 µg/mL and 0.25 µg/mL

Number of Sporozoites

Comparison of Abnormal
Differences Between Pf with no
Antibody and CSP 210
12
10
8
6
4
2
0

Spz with no ab
CSP 210 25
CSP 210 2.5
Rugged

Damaged

Surface
Membrane Tear

CSP 0.25

Abnormal Morphological Differences

Figure 3. Comparison between the amount of uncharacteristic findings of P. falciparum
sporozoites with no antibody and anti- CSP 210 induced sporozoites (as the positive
control) at 25 µg/mL, 2.5 µg/mL and 0.25 µg/mL
Anti-PfCSP MAB2A10, reactive with all P. falciparum CSP was then compared to the
sporozoites with no antibody as seen in Figure 4. This shows the number of sporozoites
exposed to anti-PfCSP MAB2A10 with a normal appearance at 25 µg/mL, 2.5 µg/mL and
15

0.25 µg/mL were 5, 13 and 61 sporozoites, respectively. For the differences within the
uncharacterized sporozoites, all types appeared other than anti-PfCSP MAB2A10 2.5
µg/mL did not have any sporozoites with a surface membrane tear.

Number of Sporozoites

Comparison Between Pf with no
Antibody and CSP 2A10
100
80
60

Spz with no ab

40

CSP 2A10 25

20

CSP 2A10 2.5

0

CSP 2A10 0.25
Smooth, elongated

Abnormal

Morphological Differences

Number of Sporozoites

Figure 4. 100 P. falciparum sporozoites with no antibody (as the negative control) were
compared with 100 anti- CSP 2A10 induced sporozoites at 25 µg/mL, 2.5 µg/mL and 0.25
µg/mL

Comparison of Abnormal
differences Between Pf with no
Antibody and CSP 2A10
50
40
30
20
10
0

Spz with no ab
CSP 2A10 25
Rugged

Damaged

Surface
Loose
Membrane Surface
Tear
Membrane

CSP 2A10 2.5
CSP 2A10 0.25

Abnormal Morphological DIfferences

Figure 5. Comparison between the amount of uncharacteristic findings of P. falciparum
sporozoites with no antibody and anti- CSP 2A10 induced sporozoites at 25 µg/mL, 2.5
µg/mL and 0.25 µg/mL
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Figure 6 displays the comparison between Pf with no antibody and Apical
Membrane Antigen 1 (AMA1). This graph represents the number of anti-AMA1 with a
normal appearance at 25 µg/mL, 2.5 µg/mL and 0.25 µg/mL were at 64, 70, and 76
sporozoites, respectively.

Number of Sporozoites

Comparison Between Pf with no
Antibody and AMA1
100
80
60

Spz with no ab

40

AMA1 25

20

AMA1 2.5

0

AMA1 0.25
Smooth, elongated

Abonormal

Morphological Differences

Figure 6. 100 P. falciparum sporozoites with no antibody (as the negative control) were
compared with 100 anti- AMA1 induced sporozoites at 25 µg/mL, 2.5 µg/mL and 0.25
µg/mL
The comparison of the abnormal morphological differences between Pf with no
antibody and AMA1 characterizes the AMA1 25 µg/mL and 2.5 µg/mL to have a rugged
appearance, only AMA 25 µg/mL to have a loose a surface membrane and all
concentrations besides the AMA1 25 µg/mL to have sporozoites with a surface membrane
tear (Figure 7).
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Number of Sporozoites

Comparison of Abnormal
Morphological Differences
between Pf with no Antibody and
AMA1
20
15
10
5
0

Spz with no ab
Damaged

Rugged

Loose
Surface
Surface Membrane
Membrane
Tear

Morphological Differences

AMA1 25
AMA1 2.5
AMA1 0.25

Figure 7. Comparison between the amount of uncharacteristic findings of P. falciparum
sporozoites with no antibody and anti- AMA1 induced sporozoites at 25 µg/mL, 2.5 µg/mL
and 0.25 µg/mL
The third type of antibody evaluated for reactivity against sporozoites was
developed against recombinant protein of cell-traversal proteins for ookinetes and
sporozoites (CelTOS), Figure 8 shows the comparison between Pf with no antibody and
CelTOS serum IgG 4D1. Here, it is indicated there were 75, 56 and 89 normal appearing
sporozoites for 25 µg/mL, 2.5 µg/mL and 0.25 µg/mL concentrations respectively.
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Number of Sporozoites

Comparison of Abnormal
Morphological Differences
between Pf with no Antibody and
anti-CelTOS 4D1
20
15
10
5
0

Spz with no ab
4D1 25
Damaged

Loose Surface
Surface
Membrane Membrane Tear

Morphological Differences

4D1 2.5
4D1 0.25

Figure 8. 100 P. falciparum sporozoites with no antibody (as the negative control) were
compared with 100 anti- CelTOS 4D1 induced sporozoites at 25 µg/mL, 2.5 µg/mL and 0.25
µg/mL
Figure 9 presents the comparison of abnormal morphological differences between Pf with
no antibody and CelTOS 4D1 at each concentration. All concentrations had a damaged
appearance or surface membrane tear and 4D1 2.5 µg/mL was the only antibody to have
sporozoites with a loose surface membrane.
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Figure 9. Comparison between the amount of uncharacteristic findings of P. falciparum
sporozoites with no antibody and anti-CelTOS 4D1 induced sporozoites at 25 µg/mL, 2.5
µg/mL and 0.25 µg/mL

The last antibody-induced treatments of sporozoites analyzed sporozoites with
antibody to CelTOS 4H12. Figure 10 shows the amount sporozoites with a normal
morphology as 42 sporozoites for 25 µg/mL, 45 sporozoites for 2.5 µg/mL and 70
sporozoites for 0.25 µg/mL.
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Figure 10. 100 P. falciparum sporozoites with no antibody (as the negative control) were
compared with 100 anti- CelTOS 4H12 induced sporozoites at 25 µg/mL, 2.5 µg/mL and
0.25 µg/mL
For the comparison of the abnormal morphological differences, Figure 11 shows that
sporozoites at all concentrations had the damaged appearance or surface membrane. 4H12

Number of Sporozoites

25 µg/mL and 2.5 µg/mL each presented with sporozoites with a loose surface membrane.
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Figure 11. Comparison between the amount of uncharacteristic findings of P. falciparum
sporozoites with no antibody and anti-CelTOS 4H12 induced sporozoites at 25 µg/mL, 2.5
µg/mL and 0.25 µg/mL
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The length and width of each sporozoite was taken as well to analyze the no antibody
sporozoites with the antibody-induced sporozoites (Table 5).
Table 5. Length (um) average and width (um) average of 100 sporozoites for each antibody
and concentration

Figure 12. Scanning Electron Microscopy image of a smooth, elongated sporozoite. The
magnification is x9,500 to have an image of the whole sporozoite with a kV of 6 and spot
size of 30.
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Figure 13. Scanning Electron Microscopy image of a damaged sporozoite. The magnification
is x11,000 to have an image of the whole sporozoite with a kV of 6 and spot size of 30.
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Figure 14. Scanning Electron Microscopy image of a sporozoite with a loose surface
membrane. The magnification is x9,000 to have an image of the whole sporozoite with a kV
of 6 and spot size of 30.
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Figure 15. Scanning Electron Microscopy image of a sporozoite with a rugged surface. The
magnification is x13,000 to have an image of the whole sporozoite with a kV of 6 and spot
size of 30.
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Figure 16. Scanning Electron Microscopy image of a sporozoite with a surface membrane
tear. The magnification is x12,000 to have an image of the whole sporozoite with a kV of 6
and spot size of 30
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Chapter Four
Discussion

The images produced by SEM do reveal uncharacterized appearances and
development in antibody-induced sporozoites consistent with the findings in previous
studies by the Adams Lab. The abnormalities were most prevalent in the highest
concentration of MAB2A10, 25 µg/mL. While there appeared to be no correlation between
the subsections of the abnormalities, the three types did appear in each of the
concentrations. These uncharacterized appearances appear to correlate with the
impairment of hepatocyte invasion. The CSP monoclonal antibody used has been shown to
abolish or diminish sporozoite infectivity (Hollingdale et. al 1984) and with this study, the
morphological changes to the sporozoite can provide insight into the mechanism in which
it occurs. When compared to anti-PvCSP210, which was the positive antibody control, antiPfCSP had more sporozoites with uncharacterized appearance.
Apical Membrane Antigen 1 (AMA1), is a microneme protein associated with
merozoite invasion (Silvie et. al., 2004). AMA1 is mostly sequestered inside the sporozoite,
however, upon exocytosis it surfaces to the external part of the sporozoite suggesting its
importance to the parasite invasion. Many studies have further investigated the proteolytic
function of AMA1 to confer a valuable strategy in preventing hepatocyte invasion. Here, we
can see that the anti-AMA1 antibody does impact the morphology of sporozoites with as
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little as 20-minute incubation time. While it is not as apparent in the lower concentrations,
the antibody itself does start appear to damage to external features of sporozoite. Even
though this microneme protein is targeted due to the impact on the erythrocytic stages, the
morphology changes shown do provide further insight in the possible inhibitory effects,
which can come from inducing the protein in early developmental stages.
With the anti-CelTOS antibodies, there were not as many sporozoites with
uncharacterized appearances. These antibodies are which are used to block hepatocyte
invasion and inhibit sporozoite mobility, are unique because they achieve nearly universal
inner leaflet cellular activity (Jimah et. al., 2016). Therefore, to have mild changes to the
external features of the sporozoites correlates with this finding. Further studies could be
useful to be able to test and analyze other potential vaccine targets and their morphological
effects on sporozoites.
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